CAMELLIA Cohort: A Longitudinal Study to Understand Sexual Health and Prevention Among Women in Alabama
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jul 14, 2022
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
To better understand contextual factors among people who identify as women in Alabama that predict STI/HIV infection and PrEP use, we will refine an existing evidence-based mobile health app (HealthMpowerment or HMP) to optimally engage and retain a digital cohort of women at-risk for HIV infection (i.e. prior infection in the past 3 months with gonorrhea or syphilis). Using a sampling strategy based on geospatial analysis of HIV-risk, we will enroll and follow our cohort longitudinally to assess factors associated with incident STI/HIV infection as well as utilization of PrEP through itera...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Self identify as a Cis-gender or Trans-gender woman
- • Age 18 - 89
- • Reported STI in past 3 months by the Alabama Department of Public Health (ADPH)
- • Gonorrhea and Syphilis negative
- • HIV negative at screening encounter
- • Live in Alabama
- • Have access to a private smart phone
- Exclusion Criteria:
- • Live outside of Alabama
- • Positive diagnosis for HIV, Gonorrhea, or Syphilis
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Birmingham, Alabama, United States
Patients applied
Trial Officials
Latesha Elopre, MD, MSPH
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials